Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 12Rituximab 9Tacrolimus 8Mycophenolic Acid 8fludarabine phosphate 7Cyclophosphamide 7Whole-Body Irradiation 6Cyclosporine 5Radiotherapy 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Busulfan 4Antilymphocyte Serum 4immunotoxin HA22 3fludarabine 3Etoposide 3Dexamethasone 3Calcium Dobesilate 3plerixafor 2merphos 2Therapeutics 2Sirolimus 2Ondansetron 2Melphalan 2Ipilimumab 2Flow Cytometry 2Diphenhydramine 2Darbepoetin alfa 2Cord Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Hairy Cell × Caves × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡